---
title: "Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284810708.md"
description: "William Blair analyst Myles Minter has reiterated a Buy rating on Alnylam Pharmaceuticals (ALNY) following strong quarterly results that exceeded expectations. The positive outlook is supported by robust growth in the TTR franchise, particularly Amvuttra, and management's reaffirmed 2026 guidance indicating significant product revenue. Minter also noted the accelerated enrollment in the Phase III TRITON trial for nucresiran, maintaining the 2030 launch timeline. H.C. Wainwright also issued a Buy rating with a $510 price target."
datetime: "2026-04-30T16:35:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284810708.md)
  - [en](https://longbridge.com/en/news/284810708.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284810708.md)
---

# Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline

William Blair analyst Myles Minter has maintained their bullish stance on ALNY stock, giving a Buy rating yesterday.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Myles Minter has given his Buy rating due to a combination of factors, including Alnylam’s strong quarterly execution and reaffirmed long‑term outlook. The company delivered revenue and earnings that exceeded both his projections and Street expectations, driven largely by robust growth in the TTR franchise, particularly Amvuttra’s continued uptake in ATTR-CM, which supports confidence in the full-year revenue targets.

Minter also highlights management’s unchanged 2026 guidance, which points to multibillion-dollar product revenue and disciplined expense control, reinforcing a compelling growth and profitability trajectory. In addition, accelerated enrollment and expansion of the Phase III TRITON trial for nucresiran, while keeping the anticipated 2030 launch timeline intact, strengthens his conviction in the company’s late-stage pipeline and future value creation potential.

Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Immunic, and Moderna. According to TipRanks, Minter has an average return of 34.6% and a 59.09% success rate on recommended stocks.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $510.00 price target.

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [TBXU.US](https://longbridge.com/en/quote/TBXU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md)
- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Thrivent Financial for Lutherans Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY](https://longbridge.com/en/news/287050595.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)